Completed PHASE3 INTERVENTIONAL 4-arm NCT00236951

Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy

A Phase III Randomized Controlled Study Comparing Iron Sucrose Intravenously to No Iron Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy

Sponsor: American Regent, Inc.

Conditions Anemia

Interventions iron sucrose injection USP stable erythropoietin therapy

Updated 9 times since 2017 Last updated: Jan 22, 2018 Started: Feb 28, 2003 Primary completion: Oct 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00236951, this PHASE3 trial focuses on Anemia and remains completed. Sponsored by American Regent, Inc., it has been updated 9 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Feb 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Feb 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Regent, Inc.

Data source: American Regent, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.